Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management
- Expected to enroll approximately 4,600 participants with obesity or overweight across two pivotal trials (AURORA-1 and AURORA-2) in the U.S., Europe, and Canada. - Global Phase III clinical program to investigate efficacy and safety of three...
CATL Announces Local Partnership, Showcases Full-Chain Storage at The Smarter E South America 2026
SÃO PAULO, Aug. 29, 2026 /PRNewswire/ -- CATL is showcasing its full energy storage ecosystem at The Smarter E South America 2026 in São Paulo from August 25 to 27, demonstrating capabilities across the entire value chain, from cell R&D and...
Noah Holdings Limited Announces Changes to the Board and Board Committees
SINGAPORE, Aug. 29, 2026 /PRNewswire/ -- Noah Holdings Limited (the "Company" or "Noah") (NYSE: NOAH and HKEX: 6686), a leading and pioneer wealth management service provider offering comprehensive one-stop advisory services on global investment and...
LifeTech Scientific Corporation Announces 2026 Interim Results
HONG KONG, Aug. 29, 2026 /PRNewswire/ -- LifeTech Scientific Corporation ("LifeTech" or the "Company", together with its subsidiaries, the "Group", stock code: 1302.HK), a medical device company specializing in minimally invasive interventional...
MetaLight (02605.HK) Announces 2026 Interim Results: Net Loss Narrows Significantly, with Adjusted Net Profitability Sustained
HONG KONG, Aug. 28, 2026 /PRNewswire/ -- MetaLight Inc. ("MetaLight" or the "Company"; Stock Code: 02605.HK), a public transit information service provider powered by time series data analytics and AI technology, today announced its interim results...
COSCO SHIPPING Ports Announces 2026 Interim Results
Weaving New Connections Empowering Smart Journeys HONG KONG, Aug. 28, 2026 /PRNewswire/ -- COSCO SHIPPING Ports Limited ("COSCO SHIPPING Ports" or "CSP" or the "Company", SEHK: 1199), the world's leading ports logistics service provider, today...
InxMed Announces Publication in The Lancet Oncology Featuring Encouraging Antitumor Activity of Ifebemtinib in Combination with Garsorasib in Previously Treated Metastatic Colorectal Cancer (CRC) Harboring KRAS G12C Mutation
NANJING, China, Aug. 28, 2026 /PRNewswire/ -- InxMed Co., Ltd ("InxMed"), a clinical-stage biotechnology company dedicated to developing innovative therapies targeting cancer treatment resistance and metastasis, today announced that the clinical...
Tigermed Announces 2026 Interim Results
HANGZHOU, China, Aug. 28, 2026 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. (300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its...
MINISO Group Announces 2026 June Quarter and Interim Unaudited Financial Results
Group Revenue Grew by 22.4% YoY in 26H1 MINISO Chinese Mainland Delivered 26.2% YoY Growth, the Highest First-half Growth Rate in Three Years, Powered by Mid-single Digit SSSG (1) MINISO North America Delivered 37.0% YoY Revenue Growth, with...
Kazia Therapeutics Limited Announces Proposed Public Offering
SYDNEY, Aug. 28, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and...